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Midlife Cardiovascular Risk Factors and Late-Life Unrecognized and
Recognized Myocardial Infarction Detect by Cardiac Magnetic
Resonance: ICELAND-MI, the AGES-Reykjavik Study
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Tamara B. Harris, MD; Lenore J. Launer, PhD; Vilmundur Gudnason, MD, PhD; Andrew E. Arai, MD
Background-—Associations of atherosclerosis risk factors with unrecognized myocardial infarction (UMI) are unclear. We
investigated associations of midlife risk factors with UMI and recognized MI (RMI) detected 31 years later by cardiac magnetic
resonance.
Methods and Results-—The Reykjavik Study (1967–1991) collected serial risk factors in subjects, mean (SD) age 48 (7) years. In
ICELAND-MI (2004–2007), 936 survivors (76 (5) years) were evaluated by cardiac magnetic resonance. Analysis included logistic
regression and random effects modeling. Comparisons are relative to subjects without MI. At baseline midlife evaluation, a
modified Framingham risk score was significantly higher in RMI and in UMI versus no MI (7.4 (6.3)%; 7.1 (6.2)% versus 5.4 (5.8)%,
P<0.001). RMI and UMI were more frequent in men (65%, 64% versus 43%; P<0.0001). Baseline systolic and diastolic blood
pressure were significantly higher in UMI (138 (17) mm Hg versus 133 (17) mm Hg; P<0.006; 87 (10) mm Hg versus 84
(10) mm Hg; P<0.02). Diastolic BP was significantly higher in RMI (88 (10) mm Hg versus 84 (10) mm Hg; P<0.02). Cholesterol
and triglycerides were significantly higher in RMI (6.7 (1.1) mmol/L versus 6.2 (1.1) mmol/L; P=0.0005; and 1.4 (0.7) mmol/L
versus 1.1 (0.7) mmol/L; P<0.003). Cholesterol trended higher in UMI (P=0.08). Serial midlife systolic BP was significantly higher
in UMI versus no MI (b [SE] = 2.69 [1.28] mm Hg, P=0.04). Serial systolic and diastolic BP were significantly higher in RMI versus
no MI (4.12 [1.60] mm Hg, P=0.01 and 2.05 [0.91] mm Hg, P=0.03) as were cholesterol (0.43 [0.11] mmol/L, P=0.0001) and
triglycerides (0.3 [0.06] mmol/L, P<0.0001).
Conclusions-—Midlife vascular risk factors are associated with UMI and RMI detected by cardiac magnetic resonance 31 years
later. Systolic blood pressure was the most significant modifiable risk factor associated with later UMI. ( J Am Heart Assoc.
2016;5:e002420 doi: 10.1161/JAHA.115.002420)
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E pidemiologic studies describe associations betweenbaseline cardiovascular risk factors and subsequent
clinically recognized myocardial infarction (RMI), typically
reported as mortality from ischemic heart disease or
composite cardiovascular end points that include MI.1–7 It is
uncertain whether traditional risk factors for RMI also account
fully for unrecognized MI (UMI) or whether UMI has additional
risk factors.8–11 By comparison with RMI, risk factors for
development of UMI are less clearly defined because of
inability to detect UMI accurately. Using usual diagnostic
clinical criteria, there can be underreporting of UMI for several
reasons including missed diagnosis, lack of symptoms,
insensitivity of 12-lead ECG, or in some cases, regression of
q waves with time.4,12–15 Therefore, UMI, which carries a
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significant risk of subsequent adverse cardiac events,16,17
may be underestimated for prospective modification of
risk.11,17,18
Advances in imaging by cardiac magnetic resonance (CMR)
with late gadolinium enhancement allow more accurate
detection of MI, including asymptomatic or unrecognized
silent events.16,19,20 Indeed, CMR is the most accurate
method available to detect myocardial scar and reports a
higher prevalence of UMI16,17,21 than other technologies,
making it more precise for population-based studies.22 The
association of UMI detected by CMR with specific risk factors
measured decades earlier has not been reported previously.
Between 1967–1991, the Icelandic Heart Association
Reykjavik Study (Reykjavik) assessed vascular risk factors in
a cohort of then middle-aged subjects born 1907–1935 and
living in the Reykjavik region.23 The study was extended in the
Age Gene/Environment Susceptibility-Reykjavik Study (AGES
2002–2006) to evaluate phenotypes of aging in organ
systems, including the cardiovascular system, in surviving
cohorts of Reykjavik.24 ICELAND-MI, a substudy of AGES,
used CMR to detect MI scarring with a high degree of
accuracy (2004–2007).16
The specific aim of this study was to investigate the
association of cardiovascular risk factors measured at midlife
with presence of UMI and RMI detected several decades later
by CMR in ICELAND-MI. We hypothesized that (1) baseline
midlife cardiovascular risk factors that are important for
clinically RMI would also be associated with UMI detected at
late life by accurate CMR methodology, and (2) serial midlife
measures of cardiovascular risk factors would be associated
with both UMI and RMI at late life.
Methods
The Icelandic Reykjavik Study was a cohort of 30 795
randomly selected subjects born between 1907 and 1935
living in the Reykjavik area in 1967. Serial cardiovascular
measures and covariates were collected from the Reykjavik
cohort between 1967 and 1996 to provide cross-sectional
and longitudinal data. The AGES-Reykjavik Study (2002–
2006) was designed to study 5764 subjects aged 66 to
98 years old randomly selected from the surviving Reykjavik
cohort.24 All participants signed a written informed consent
and the study was approved by the National Bioethics
Committee in Iceland and the Institutional Review Board of
the Intramural Research Program of the National Institute on
Aging.
In 2004, ICELAND-MI was initiated to investigate preva-
lence of vascular risk factors and the presence of RMI and
UMI identified by late gadolinium enhancement CMR. The
sample size for this cohort has been previously described
(n=936).16 Recruitment occurred in 2 phases. Phase 1 was a
random sample of the AGES-Reykjavik cohort, which enrolled
702 subjects. Phase 2 enrollment specifically recruited
subjects with diabetes and enrolled another 290 subjects.
After exclusion of subjects who did not undergo the CMR and
subjects with technical problems that prevented image
analysis, the final sample size was 936 subjects for the
current study.
Magnetic Resonance Imaging
All CMR studies were performed on a 1.5-T Signa Twinspeed
scanner using a 4-element cardiac phased–array coil (General
Electric Medical Systems, Waukesha, WI) as previously
described.16,25 Images were acquired during breath-hold and
triggered to the ECG or to pulse oximetry if ECG gating was
suboptimal.
Late gadolinium enhancement imaging has been validated
in both small and large animals, and in an international
randomized controlled trial.26–29 Imaging was performed to
evaluate MI scar, typically 6 to 15 minutes after injection of
gadopentetate dimeglumine at low dose (0.1 mmol/kg;
Magnevist, Schering AG, Berlin, Germany), using a phase-
sensitive segmentation gradient echo inversion recovery
sequence.25 Calculated median glomerular filtration rate
was 69 (interquartile range 59–82) mL/min per 1.73 m2
and no subject had significant renal failure.16,30
Using the 17-segment standardized model of the American
Heart Association,31 the diagnosis of MI was based on
consensus of 2 cardiologists experienced in CMR and blinded
to subject clinical characteristics. For each segment, MI scar
was considered present if the detected lesion had endocardial
involvement and followed a coronary distribution. Scar
patterns considered atypical for MI were not designated as
MI. The size of left ventricular infarct was expressed as a
percentage of total left ventricle.
Modifiable Risk Factors and Modified
Framingham Score at Midlife
By design, a portion of the Reykjavik cohort were examined up
to 5 times between 1967 and 199124 to document modifiable
risk factors including lipid levels, blood pressure (BP),
smoking, diabetes, obesity measured as body mass index,
and physical activity. Other reported modifiable risk factors32
including psychosocial factors, nutrition, and alcohol use were
not assessed in this study.
Serum cholesterol and triglycerides were measured after
an overnight fast using a chemical colorimetric method.3,33,34
Supine BP was measured twice in fasting subjects by a
nurse after 5 minutes of rest between 8:30 AM and 10:30 AM.
The mercury “Erkameter” wall-model sphygmomanometer
(Erka, Germany) with cuff including a rubber bladder
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15932 cm, and total length 66 cm was used. BP was the
average of the 2 measures.35
Body mass index was calculated as weight (kilograms)
divided by height2 (meters). Physical activity was assessed
using a questionnaire that asked about physical activity
assessed as 1=never, 2=rarely, 3=occasionally, 4=moderate,
5=high.
A modified Framingham percentage risk was calculated
using Framingham score variables that included age, gender,
total cholesterol, smoking status, systolic BP, diabetes, and
use of antihypertensive treatment, but excluded high-density
lipoprotein cholesterol, which was not estimated in the
Reykjavik Study.36,37
Covariates
Covariates included demographic information (age, sex), and
risk factors associated with cardiovascular events assessed at
midlife included smoking history, glucose level, and use of
antihypertensive drugs.
Statistical Analysis
An adjudication committee determined whether or not subjects
had a clinically recognized MI (RMI) event based on subject
history supported by hospital or surveillance records. Unrec-
ognized MI (UMI) was defined as MI detected by CMR but
without evidence of clinical RMI from hospital or surveillance
records.16 The group without MI was the remainder of subjects
who did not have a clinical event attributed to RMI by the
adjudication committee or UMI detected by CMR.
Baseline characteristics at midlife were compared between
groups first with and without MI, and then for RMI, UMI, or no
MI using logistic regression adjusted for sex and midlife age,
and then further adjusted for use of antihypertensive drugs,
blood glucose, smoking, all at midlife, and age at late life.
Multivariate analysis was performed by logistic regression to
compare all MI versus no MI and by polynomial logistic
regression to compare RMI and UMI with no MI.
Serial systolic and diastolic BP, serum cholesterol, and
triglyceride courses were estimated visually by plotting mean
values at each midlife measure, stratified by presence of RMI
or UMI or no MI.
A random-effects model (with random intercept and slope
function) was used to model the trends in midlife cardiovas-
cular measures by presence of recognized, unrecognized, or
no MI. This approach takes into account the correlation of
within-individual measures, and the fact that there are
unequal numbers of observations per individual. The random
intercept and slope allow the estimates to vary on an
individual level. Each model was tested for a significant
interaction term between RMI or UMI and age to test whether
the slopes of the cardiovascular risk factors differ between
the 3 groups.
The models were first adjusted for sex, and age at midlife
and late life, and then further adjusted for midlife variables
including smoking history (never versus ever), use of BP-
lowering medication, and blood glucose.
Statistical analysis was performed using SAS 9.3 (SAS
Institute Inc, Cary, NC). Data were expressed asmean (standard
deviation) or percentage (number). In all analyses, the conven-
tional a-level of 0.05 was used for significance testing. The
mean per time point for each variable was plotted according to
the presence or absence of MI using R software version 2.13.0
(R Foundation for Statistical Computing, Vienna, Austria).38
The analytic sample consisted of 936 subjects described
previously who completed the CMR examination on average
31 (3) years after the baseline Reykjavik visit.16 There were 1
or more assessments of risk factors in the subjects at midlife;
460 had 1 assessment, 185 had 2 assessments, 42 had 3
assessments, 93 had 4 assessments, and 156 had 5
assessments between 1967 and 1991. The subjects who
came for 1 rather than for multiple visits were older (49.4
(6.4) versus 46.2 (7.9) years; P<0.001), and less likely to be
men (43.1% versus 53.2%, P=0.04), but more likely to smoke
(35.1% versus 8.8%, P<0.001), be diabetic (1.7% versus 0.2%,
P=0.05), and to take antihypertensive agents (7.6% versus
1.0%, P<0.001; Table 1).
Results
Baseline Midlife Cardiovascular Risk Factors and
Subsequent MI in Late Life
At late-life ICELAND-MI follow-up, the mean age of the group
was 76.7 (5.3) years. Twenty-six percent (248/936) of subjects
had MI when assessed by CMR in late life and of these, the
majority were unrecognized (63%; 157/248), whereas 37%
(91/248) of subjects had a clinically recognized event.16
Among clinically RMI, 22 subjects (24% RMI or 9% all MI) did not
have evidence of myocardial scar by CMR, and 10/22 (45%) of
these subjects had undergone a revascularization procedure.
At the baselinemidlife assessment, themodified Framingham
risk score was significantly higher in the entire MI group
(7.2 [6.2]% versus 5.4 [5.8]%, P<0.001; Table 2). There were
significantly more men in the MI group compared with the no MI
group (64.1% versus 42.6%; P<0.001; Table 2). TheMI group had
a significantly higher systolic and diastolic BP (138 [16] versus
133 [17] mm Hg; P=0.002 and 87 [10] versus 84 [10] mm Hg;
P=0.002), and serum cholesterol (6.52 [1.15] versus 6.24 [1.07]
mmol/L; P=0.001). Serum triglycerides were significantly higher
only after adjustment for sex and age at mid- and late life, and
midlife covariates (1.31 [0.68] versus 1.12 [0.64] mmol/L,
P=0.03).
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The modified Framingham risk score was significantly
higher in RMI and in UMI compared with no MI (7.4 [6.3]%
and 7.1 [6.2]% versus 5.4 [5.8]%, P=0.0003; Table 3). The
percentage of men was higher in RMI and in UMI than in
no MI (Table 3). Baseline systolic BP was significantly
higher in UMI, and trended higher in RMI (P=0.06). Baseline
diastolic BP was elevated significantly in both RMI and UMI
(Table 3). Serum cholesterol and triglycerides were signif-
icantly higher in RMI (Table 3). Serum cholesterol trended
higher in UMI (P=0.08). When risk factors for RMI were
compared with risk factors for UMI, there were not
significant differences.
In a multivariate analysis of baseline midlife risk factors,
gender, systolic BP, and serum cholesterol were all signifi-
cantly higher in all MI vs. no MI (Table 4). Similarly, sex, serum
cholesterol, and triglycerides were significantly associated
risk factors for RMI, whereas sex and systolic BP were the
most significant factors for UMI (Table 4).
The percentage size of UMI was smaller than the
percentage size of RMI (6 [7]% versus 14 [13]%, P<0.0001).
Serial Midlife Cardiovascular Risk Factors and
Subsequent MI
Midlife BP and MI
Figure shows the trend in midlife systolic and diastolic BP and
MI. In random effects models I and II, systolic BP was
Table 1. Characteristics of Subjects With One Versus






One Visit Multiple Visits
P Value*n=459 n=477
Age 49.4 (6.4) 46.2 (7.9) <0.0001
Men, % (n) 43.1 (198) 53.2 (254) 0.04
Height, cm 170.4 (8.6) 171.9 (9.1) 0.26
Weight, kg 74.1 (12.6) 75.3 (13.1) 0.80
BMI, kg/m2 25.4 (3.5) 25.4 (3.4) 0.41
Tobacco use, % (n)
Ever smoker 58.8 (270) 14.3 (68) <0.0001
Current smoker 35.1 (161) 8.8 (42) <0.0001
Antihypertensive
medication, % (n)
7.6 (35) 1.0 (5) 0.0003
Diabetes mellitus,
% (n)
1.7 (8) 0.2 (1) 0.05
Blood pressure, mm Hg†
Systolic 133.8 (17.2) 134.1 (16.8) 0.25




6.34 (1.14) 6.29 (1.06) 0.57
Triglycerides,
mmol/L‡
1.18 (0.69) 1.16 (0.63) 0.84
Fasting glucose,
mmol/L
80.3 (10.9) 80.5 (11.2) 0.54
Creatinine,
lmol/L
85.4 (13.8) 85.5 (14.7) 0.08
BMI indicates body mass index; BP, blood pressure; M (SD), mean (standard deviation).
*Logistic regression to compare subjects with one or more than one visit, adjusted for
age and sex.
†Adjusted for antihypertensive medications.
‡Adjusted for cholesterol.
Table 2. Baseline Characteristics of Population at Midlife by
Presence of Late-Life Myocardial Infarction Detected by





Age 48.1 (7.0) 47.7 (7.5) <0.06
Men, % (n) 64.1 (159) 42.6 (293) <0.001
Height, cm 172.7 (8.6) 170.6 (8.9) 0.08
Weight, kg 76.7 (12.8) 74.0 (12.8) 0.55
BMI, kg/m2 25.6 (3.4) 25.4 (3.5) 0.84
Tobacco use, % (n)
Ever smoker 35.5 (88) 36.3 (250) 0.38
Current smoker 23.8 (59) 20.9 (144) 0.44
Antihypertensive medication,
% (n)
5.2 (13) 3.9 (27) 0.45
Diabetes mellitus, % (n) 0.4 (1) 1.2 (8) 0.37
Blood pressure, mm Hg†
Systolic 138 (16) 133 (17) 0.002
Diastolic 87 (10) 84 (10) 0.002
Blood sample
Cholesterol, mmol/L 6.52 (1.15) 6.24 (1.07) 0.001
Triglycerides, mmol/L‡ 1.31 (0.68) 1.12 (0.64) 0.09
Fasting glucose, mmol/L 4.5 (0.5) 4.5 (0.6) 0.25
Creatinine, lmol/L 88.0 (17.6) 88.0 (17.6) 0.56
Midlife physical activity§ 2.8 (1.3) 2.9 (1.3) 0.23
Modified Framingham
% riskk
7.2 (6.2) 5.4 (5.8) <0.0001
BMI indicates body mass index; M (SD), mean (standard deviation); MI, myocardial
infarction; MR, magnetic resonance imaging.
*Logistic models to compare the overall difference between the groups adjusted for age
and sex.
†Adjusted for antihypertensive medications.
‡Adjusted for cholesterol.
§Exercise: 1=never, 2=rarely, 3=occasionally, 4=moderate, 5=high.
kModel not corrected because age and sex are included in risk score.
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consistently significantly higher by 3.2 mm Hg in the entire
MI group (P=0.003; Table 5). Serial systolic BP was signifi-
cantly higher for both RMI and UMI (P=0.01 and 0.04,
respectively; Figure, Table 5). Diastolic BP was consistently
significantly higher by 1.5 mm Hg in the entire MI group
(P=0.02; Figure, Table 5), but only RMI, not UMI, was the
significant contributor to this finding.
Midlife serum cholesterol and triglycerides and MI
In random effects models I and II, serial cholesterol was
significantly higher by 0.25 mmol/L in the entire MI group
(P=0.001; Figure, Table 5). Similarly triglycerides were signif-
icantly higher by a mean of 0.15 mmol/L in the MI group
(P=0.02; Figure, Table 5). For both cholesterol and triglyc-
erides, only RMI was significantly related to blood levels in the
models (Figure, Table 5).
Other modifiable risk factors and MI
There was no significant trend in midlife body mass index or
blood glucose level and later MI (Table 5). Physical activity
was marginally lower in RMI.
Discussion
In this cohort, midlife atherosclerotic risk determined using a
modified Framingham risk score was associated significantly
with all late-life MI. Importantly, the modified Framingham
percentage risk score was significantly higher not only in RMI,
but also in UMI. It is perhaps surprising that late-life RMI and
UMI are associated strongly with a midlife summary risk score
obtained 3 decades earlier and derived from single baseline
measures of traditional risk factors, which could be prone to
measurement errors and any interim personal changes.39
Table 3. Baseline Characteristics of Population at Midlife by Presence of Late-Life Recognized or Unrecognized Myocardial
Infarction Detected by Cardiac MR at ICELAND_MI
Baseline Midlife Risk Factors, M (SD) Recognized MI Unrecognized MI No MI P Value*
N 91 157 688
Age 47.9 (6.6) 48.3 (7.2) 47.7 (7.48) 0.07
Men, % (n) 64.8 (59)¶ 63.7 (100)¶ 42.6 (293) <0.0001
Height, cm 172.7 (8.9) 172.7 (8.5) 170.6 (8.9) 0.20
Weight, kg 75.9 (12.9) 77.1 (12.8) 74.0 (12.8) 0.49
BMI, kg/m2 25.4 (3.5) 25.8 (3.4) 25.4 (3.5) 0.63
Tobacco use, % (n)
Ever smoker 38.5 (35) 33.8 (53) 36.3 (250) 0.51
Current smoker 26.4 (24) 22.3 (35) 20.9 (144) 0.59
Antihypertensive medication, % (n) 3.3 (5) 5.1 (8) 3.9 (27) 0.68
Diabetes mellitus, % (n) 0 0.6 (1) 1.2 (8) 0.89
Blood pressure, mm Hg†
Systolic 137.4 (15.1)# 138.3 (16.9)** 132.6 (17.0) 0.01
Diastolic 87.7 (9.8)†† 87.2 (10.3)†† 83.7 (10.0) 0.006
Blood sample
Cholesterol, mmol/L 6.67 (1.14)‡‡ 6.43 (1.15)§§ 6.24 (1.07) 0.001
Triglycerides, mmol/L‡ 1.40 (0.72)kk 1.25 (0.66) 1.12 (0.65) 0.009
Fasting glucose, mmol/L 80.2 (8.6) 80.6 (9.6) 80.3 (11.6) 0.48
Creatinine, lmol/L 89.2 (13.2) 88.4 (14.9) 84.3 (14.1) 0.77
Midlife physical activity§ 2.6 (1.3) 2.9 (1.2) 2.88 (1.25) 0.18
Modified Framingham % riskk 7.4 (6.3)¶¶ 7.1 (6.2)¶¶ 5.4 (5.8) 0.0003
BMI indicates body mass index; M (SD), mean (standard deviation); MI, myocardial infarction; MR, magnetic resonance imaging.
*ANOVA and logistic models to compare recognized MI and unrecognized MI with no MI adjusted for age and gender.
†Adjusted for antihypertensive medications.
‡Adjusted for serum cholesterol.
§Exercise: 1=never, 2=rarely, 3=occasionally, 4=moderate, 5=high.
kModel not corrected for age and gender because these are included in the score.
¶P≤0.0001; #P=0.06; **P≤0.006; ††P<0.02; ‡‡P=0.0005; §§P=0.08; kkP≤0.003; ¶¶P<0.05.
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CMR is the most accurate technique available to detect
myocardial scar whether recognized or unrecognized, and the
presence of scar is associated with a worse prognosis.16 In
earlier studies in which detection of MI was based on clinical
and electrocardiographic findings, large numbers of subjects
were needed to detect relationships.5 In this study, CMR
detected recognized and unrecognized MI in 26% of subjects
in this cohort of 936 subjects. A small percentage of clinically
RMI subjects had normal CMR. Subjects with clinically RMI
and yet no myocardial scar by CMR could be explained by
revascularization, reversible pathology such as myocarditis, or
a clinical misdiagnosis.
Midlife measures of systolic and diastolic BP and choles-
terol were associated significantly with the presence of all
late-life MI. Although many reports describe the association of
hypertension with increased cardiovascular mortality,2,4,14,40–
43 this unique data set links small increases in BP and
cholesterol at midlife with UMI and RMI evaluated by CMR on
average 31 years later.
In ICELAND-MI, serial midlife measures of both systolic and
diastolic BP remained consistently higher in the MI group
without a change in trend with time. Multiple factors may have
contributed to persistent elevation of BP in the MI group
including increasing age, changes in vascular compliance, and
patient compliance with therapy.44–47 Although antihyperten-
sive therapy reduces clinical MI in randomized controlled
trials,48 translation of trial results into effective control of BP
during 25 years or more is challenging, despite increased drug
therapy with time.16 Our results indicate that even minor
elevations of BP in the prehypertension range may be a risk for
later MI, and are consistent with recent data from the Chicago
Heart Association.49 These data raise questions about target
pressures recommended by recent European guidelines and US
reports.50–52 The data may also be complementary to the
SPRINT trial in which preliminary reports suggest that aggres-
sive lowering of BP below current thresholds may be benefi-
cial.53
Both baseline and serial cholesterol levels were signifi-
cantly associated with all later MI. There are no data on high-
density lipoprotein cholesterol or on use of statins at midlife
because these drugs were licensed in the late 1980s toward
the end of the Reykjavik study. The association between
serum triglycerides and all MI, independent of serum choles-
terol, is consistent with prior combined mortality and
morbidity data.54,55
In this study, systolic BP was the most significant
modifiable risk factor for UMI. There was also a trend for
higher serum cholesterol in the UMI group. Equal prevalence
of risk factors has been reported for both recognized and
unrecognized MI detected by electrocardiographic criteria,11
but our study differs from earlier reports because this is an
older cohort of late-life survivors of the original Reykjavik
study in whom MI was detected by CMR. Prevalence and risk
factors of UMI demonstrate substantial variability, depending
on the population under study.8
The size of unrecognized MI was smaller than RMI, a
finding that has been reported in other studies.21 UMI shares
some characteristics with silent cerebral infarctions, which
are of smaller size in general, increase in prevalence with age,
have few identified risk factors except age and hypertension,
and portend later adverse cerebral events.56,57 Whether UMI
differs from RMI by presence of small vessel disease or in
Table 4. Multivariate Analysis of Baseline Midlife Risk Factors With Late-Life Myocardial Infarction Using Logistic Regression
Baseline Midlife Risk Factors
All MI* Recognized MI* Unrecognized MI*
Odds Ratio (95% Confidence Interval)
Age 1.02 (0.99, 1.04) 1.00 (0.96, 1.03) 1.03 (1.00, 1.05)
Sex 2.91 (1.88, 4.51) 2.69 (1.41, 5.12) 3.08 (1.83, 5.19)
Cholesterol 1.18 (1.01, 1.37) 1.39 (1.12, 1.72) 1.06 (0.89, 1.28)
Systolic BP 1.01 (1.00, 1.02) 1.01 (1.00, 1.03) 1.02 (1.00, 1.03)
BMI, kg/m2 0.98 (0.94, 1.04) 0.95 (0.87, 1.02) 1.01 (0.95, 1.07)
Glucose 0.99 (0.97, 1.01) 0.99 (0.97, 1.01) 0.99 (0.97, 1.01)
Serum creatinine 0.52 (0.14, 1.97) 0.89 (0.13, 6.04) 0.38 (0.08, 1.87)
Serum triglyceride 1.27 (0.99, 1.62) 1.40 (1.02, 1.93) 1.17 (0.87, 1.59)
Physical activity 1.09 (0.92, 1.29) 0.99 (0.77, 1.28) 1.15 (0.94, 1.41)
Hypertension medications 0.82 (0.38, 1.74) 0.76 (0.27, 2.26) 0.84 (0.34, 2.03)
Smoking 1.21 (0.87, 1.70) 1.08 (0.66, 1.76) 1.31 (0.87, 1.96)
BMI indicates body mass index; BP, blood pressure; MI, myocardial infarction.
*Compared with no MI group.
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terms of pathophysiologic mechanisms cannot be addressed
in this study.
There are a number of limitations to this study. The
modified Framingham risk score does not include measures of
high-density lipoprotein cholesterol, and yet is still associated
with later RMI and UMI. Also, the subjects are survivors still
alive 31 years after the Reykjavik study. The prevalence of
RMI versus UMI may alter with time, and so the relation of risk
factors such as diabetes or smoking to a lethal disease could
be underestimated (ie, survivor bias). MI itself can alter BP or
cholesterol through pathophysiologic change, or prescription
of drugs or diet, but the baseline midlife Reykjavik data are
unlikely to have this limitation because the mean age was
48 years and probably before onset of MI in most cases. In
the 1970s and 1980s, cardiovascular risk factor management
was not as well defined as in current practice guidelines,
which have lower thresholds for intervention for prehyperten-
sion and hypercholesterolemia.50,52,58 In the Reykjavik study,
the baseline mean systolic and diastolic BPs at midlife were in
the prehypertension range and higher than mean BPs
reported in a recent National Health and Nutrition Examina-
tion Survey.59
In this Icelandic cohort, atherosclerotic risk factors at
midlife are associated with both UMI and RMI detected by
CMR 31 years later. Among modifiable midlife risk factors
studied, systolic BP was the most significant factor associated
with UMI, although the impact of other important risk factors
such as diabetes could not be addressed in this report. The
paper highlights the finding that even minor elevations of
mean levels of cardiovascular risk factors are associated with
later RMI and UMI. From a public health perspective, it may be
useful to test whether outcomes improve with early aggres-






















































































Figure. Five-year trends in midlife systolic (A) and diastolic (B) blood pressure, cholesterol (C), and
triglycerides (D) with increasing age related to all MI and recognized and unrecognized MI (red line=all MI;
blue line=recognized MI; green line=unrecognized MI; black line=no MI). MI indicates myocardial infarction.
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Table 5. Association of Serial Midlife Risk Factors and Both Recognized and Unrecognized Myocardial Infarction Assessed by CMR
in Later Life
Risk Factors Comparing MI vs No MI
Model I* Model II†
b (SE) P Value b (SE) P Value
Serial systolic blood pressure, mm Hg‡
All MI vs no MI 3.20 (1.11) 0.004 3.21 (1.08) 0.003
Unrecognized MI 2.76 (1.31) 0.04 2.69 (1.28) 0.04
Recognized MI 4.03 (1.64) 0.01 4.12 (1.60) 0.010
Serial diastolic blood pressure, mm Hg‡
All MI vs no MI 1.50 (0.63) 0.02 1.50 (0.62) 0.02
Unrecognized MI 1.18 (0.73) 0.11 1.18 (0.73) 0.11
Recognized MI 2.05 (0.94) 0.03 2.05 (0.91) 0.03
Serial cholesterol, mmol/L
All MI vs no MI 0.25 (0.08) 0.001 0.25 (0.08) 0.001
Unrecognized MI 0.14 (0.09) 0.11 0.14 (0.09) 0.11
Recognized MI 0.43 (0.11) 0.0001 0.43 (0.11) 0.0001
Serial triglycerides, mmol/L§
All MI vs no MI 0.15 (0.05) 0.002 0.15 (0.05) 0.002
Unrecognized MI 0.07 (0.06) 0.25 0.07 (0.06) 0.24
Recognized MI 0.31 (0.07) <0.0001 0.30 (0.06) <0.0001
Serial glucose
All MI vs no MI 0.61 (0.58) 0.60 0.60 (0.58) 0.30
Unrecognized MI 0.48 (0.69) 0.48 0.43 (0.69) 0.53
Recognized MI 0.82 (0.85) 0.33 0.88 (0.84) 0.30
Serial body mass index, kg/m2
All MI vs no MI 0.13 (0.25) 0.60 0.15 (0.25) 0.54
Unrecognized MI 0.33 (0.30) 0.30 0.36 (0.29) 0.23
Recognized MI 0.22 (0.38) 0.38 0.20 (0.37) 0.60
Midlife physical activityk
All MI vs no MI 0.10 (0.06) 0.11 0.09 (0.06) 0.17
Unrecognized MI 0.00 (0.08) 0.96 0.01 (0.08) 0.85
Recognized MI 0.26 (0.09) 0.006 0.25 (0.09) 0.007
CMR indicates cardiac magnetic resonance imaging; b (SE), coefficient (standard error); MI, myocardial infarction.
*Model 1, mixed model adjusted for midlife age, late-life age, and sex.
†Model 2, mixed model adjusted for midlife age, late-life age, sex, midlife smoking, midlife antihypertensive medication, and midlife serum glucose.
‡Adjusted for antihypertensive medications.
§Adjusted for cholesterol.
kPhysical activity: 1=never, 2=rarely, 3=occasionally, 4=moderate, 5=high.
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